Terms: = Ovarian cancer AND NCOR2, SMRTE-tau, 9612, ENSG00000196498, SMRTE, TNRC14, TRAC-1, SMRT, CTG26, TRAC1 AND Prognosis
4 results:
1. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
2. A Novel Notch-Related Gene Signature for prognosis and Immune Response Prediction in ovarian cancer.
Pi Y; Sun F; Zhang Z; Liu X; Lou G
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512088
[No Abstract] [Full Text] [Related]
3. Nuclear receptor co-repressor ncor2 and its relation to GPER with prognostic impact in ovarian cancer.
Reichenbach J; Fraungruber P; Mayr D; Buschmann C; Kraus FBT; Topalov NE; Chelariu-Raicu A; Kolben T; Burges A; Mahner S; Kessler M; Jeschke U; Czogalla B; Trillsch F
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8719-8728. PubMed ID: 37131060
[TBL] [Abstract] [Full Text] [Related]
4. Over-Expression of TBL1XR1 Indicates Poor prognosis of Serous Epithelial ovarian cancer.
Ma M; Yu N
Tohoku J Exp Med; 2017 Mar; 241(3):239-247. PubMed ID: 28344213
[TBL] [Abstract] [Full Text] [Related]
